Data Insights
No filters selected
No filters selected
No filters selected
No filters selected
ONC-206 by Chimerix for High-Grade Glioma: Likelihood of Approval
ONC-206 is under clinical development by Chimerix and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I...
Dordaviprone hydrochloride by Chimerix for Prostate Cancer: Likelihood of Approval
Dordaviprone hydrochloride is under clinical development by Chimerix and currently in Phase I for Prostate Cancer. According to GlobalData, Phase...
Dordaviprone hydrochloride by Chimerix for Relapsed Multiple Myeloma: Likelihood of Approval
Dordaviprone hydrochloride is under clinical development by Chimerix and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...
Dordaviprone hydrochloride by Chimerix for Refractory Multiple Myeloma: Likelihood of Approval
Dordaviprone hydrochloride is under clinical development by Chimerix and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...